logo
Menu

We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer

< Back

Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer

Drugs

Cancer and Palliative Care

February 2018


Prostate cancer is cancer of the prostate gland (a small organ in a man’s pelvis) and is the second most common cancer in the UK. There are three stages: localised, locally‐advanced and advanced (or metastatic) prostate cancer. The symptoms may vary depending on the stage of cancer but can include pain, tiredness, problems emptying the bladder and the bowels. About half of men diagnosed with locally‐advanced prostate cancer will see their cancer spread to other body organs (i.e. becoming metastatic). Prostate cancer growth and spread depends on the hormone, testosterone. Cancer that do not respond to hormonal treatment to reduce the level of testosterone are known as castrationresistant prostate cancer.
Darolutamide is a hormonal drug under development for castration resistant prostate cancer that has not spread (non‐metastatic). It acts by blocking testosterone receptors from getting activated on the cancer cells and consequently reducing the size of the cancer. Darolutamide is taken orally twice a day. If licenced, darolutamide will provide an additional treatment option for men with non‐metastatic castration‐resistant prostate cancer that are at high risk of their cancer spreading to other parts of the body.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts